Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

118 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Infliximab for IPILIMUMAB-Related Colitis-Letter.
Arriola E, Wheater M, Karydis I, Thomas G, Ottensmeier C. Arriola E, et al. Clin Cancer Res. 2015 Dec 15;21(24):5642-3. doi: 10.1158/1078-0432.CCR-15-2471. Clin Cancer Res. 2015. PMID: 26672088 No abstract available.
Assessment of neuronal autoantibodies in patients with small cell lung cancer treated with chemotherapy with or without ipilimumab.
Hardy-Werbin M, Arpí O, Taus A, Rocha P, Joseph-Pietras D, Nolan L, Danson S, Griffiths R, Lopez-Botet M, Rovira A, Albanell J, Ottensmeier CH, Arriola E. Hardy-Werbin M, et al. Among authors: arriola e. Oncoimmunology. 2017 Nov 27;7(2):e1395125. doi: 10.1080/2162402X.2017.1395125. eCollection 2018. Oncoimmunology. 2017. PMID: 29308329 Free PMC article.
Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer.
Hardy-Werbin M, Rocha P, Arpi O, Taus Á, Nonell L, Durán X, Villanueva X, Joseph-Pietras D, Nolan L, Danson S, Griffiths R, Lopez-Botet M, Rovira A, Albanell J, Ottensmeier C, Arriola E. Hardy-Werbin M, et al. Among authors: arriola e. Oncoimmunology. 2019 Mar 27;8(6):e1593810. doi: 10.1080/2162402X.2019.1593810. eCollection 2019. Oncoimmunology. 2019. PMID: 31069160 Free PMC article.
Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC.
Arriola E, Wheater M, Galea I, Cross N, Maishman T, Hamid D, Stanton L, Cave J, Geldart T, Mulatero C, Potter V, Danson S, Woll PJ, Griffiths R, Nolan L, Ottensmeier C. Arriola E, et al. J Thorac Oncol. 2016 Sep;11(9):1511-21. doi: 10.1016/j.jtho.2016.05.028. Epub 2016 Jun 11. J Thorac Oncol. 2016. PMID: 27296105 Free PMC article. Clinical Trial.
118 results